Lithium has been tried for few years as a treatment for neurodegenerative diseases, at lower doses than used for bipolar disorder. However, the conventional medications had difficulty crossing the blood-brain barrier and there were still side effects. A new rat study, using a French formulation that does cross the blood-brain barrier, got excellent results with an Alzheimer's model at doses 400 times lower.
The new lithium formulation was then applied to a rat transgenic model expressing human mutated proteins causative of Alzheimer's, an animal model they had created and characterized. This rat develops features of the human Alzheimer's disease,...
... administered at early amyloid pathology stages in the Alzheimer's-like transgenic rat. These results were remarkably positive ...
"From a practical point of view our findings show that microdoses of lithium in formulations such as the one we used, which facilitates passage to the brain through the brain-blood barrier while minimizing levels of lithium in the blood, sparing individuals from adverse effects, should find immediate therapeutic applications," says Dr. Cuello.
NP03 is a disease-modifying nano dose formulation of lithium citrate in an AONYS® reverse microemulsion. NP03 allows the delivery of lithium citrate to all tissues with a strong therapeutic efficacy at doses two orders of magnitude lower than those used in currently marketed lithium specialties.
AONYS® is a mix of lipidic components that spontaneously assemble into a water-in-oil microemulsion. The active agent is solubilized in the aqueous phase of the microemulsion, within reverse micelles of 4 to 5 nm in diameter.
AONYS® allows the administration of low doses of water-soluble pharmaceutical active ingredients. The final product is deposited on the mucosa of the mouth and then transported by lipoproteins and delivered directly into the cytoplasm of the cells of the whole body via lipoprotein cell receptors.
Let's hope they complete clinical trials promptly!